Safety and pharmacokinetic study of respiratory syncytial virus fusion inhibitor GS-5806
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2018
Price : $35 *
At a glance
- Drugs Presatovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- 17 Apr 2018 Results of pooled data from two phase 1 trial, were published in the Journal of Clinical Pharmacology.
- 07 Oct 2014 New trial record
- 06 Sep 2014 Results presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.